Skip to main content
OpenTrials
Completed

NCT Number: NCT03628235

HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States

Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregiver support, and long-term care, which lead to substantial burden of illness. Very little data are available on the direct or indirect costs for HD. The direct medical costs of HD in the US have been summarized from retrospective commercial and Medicaid claims data analysis. The indirect and out-of-pocket costs of HD in the US have not been quantified. This study will help to bridge these gaps.

This study is a single-assessment, cross-sectional online survey administered to Huntington disease gene expansion carriers (HDGECs) and companions of HDGECs by HD stage to understand the indirect and out-of-pocket costs of Huntington's disease in the US.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

Loading trial locations.

About this study

The survey collects the following data from each HDGEC and companion:

  • Participant demographics (for HDGECs and companion)
  • Informal care received (for HDGECs only)
  • Out of pocket HD costs (for HDGECs and companion)
  • Current employment status (for HDGECs and companion)
  • Non-work and work care giving time that companion spends taking care of HDGEC (for companion only)
  • Work Productivity and Activity Impairment (WPAI) Questionnaire (for HDGECs and companion)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for HDGECs:

  • Identified as an active participant in Enroll-HD (participants who have completed their last on site Enroll-HD visit within approximately 15 months)
  • Able to provide online or written informed consent. A LAR for HDGEC can provide written consent, if applicable
  • Identified as a participant with clinically diagnosed HD and has a CAG length ≥ 40
  • Site PI has access to HDGEC's medical records for the purpose of completing the Resource Utilization Questionnaire
  • Able to speak and understand both verbal and written English
  • Has adult onset of disease (disease symptoms manifested at age 20 years or older)
  • Has access to a computer/tablet/smartphone (if compatible) and internet services

Stage classification of HDGECs:

  • Early stage HDGEC: CAG length ≥ 40; DCL = 4, TFC ≥ 11
  • Middle stage HDGEC: CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
  • Late stage HDGEC: CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6

Exclusion criteria

for HDGECs:

HDGECs will be excluded from the study if they have significant cognitive or any other impairment sufficient to interfere with study associated tasks as judged by the Site PI or Site PI's designee (exceptions will be made if a companion/LAR completes the survey on their behalf).

Inclusion criteria

for companions:

  • Able to provide online or written informed consent
  • Identified as the primary provider (unpaid) of supportive care of an HDGEC (HDGEC must be an Enroll-HD participant and have a CAG length ≥ 40 and have adult onset of disease (disease symptoms manifested at age 20 years or older))
  • Able to speak and understand both verbal and written English
  • Aged 21 years or older at time of survey
  • Has access to a computer/tablet/smartphone (if compatible) and internet services and has the technical skills required to complete an online survey

Exclusion criteria

for companions:

Companions will be excluded from the study if they are identified as paid or salaried caregivers; however, the HDGECs for whom they care may still be included in the study.

Treatment and study plan

Online survey

Behavioral

Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions

Primary outcomes

  1. Quantify the indirect costs associated with productivity loss for HDGECs and companions

    Time frame: 12 months

    Productivity loss is measured by annual lost wages and it is collected in the survey's employment questionnaires and WPAI

  2. Quantify out-of-pocket expenses for HDGECs and companions

    Time frame: 12 months

    The indirect costs associated with the total annual out-of-pocket expenses.

  3. Identify the indirect costs associated with informal care received for HDGECs

    Time frame: 12 months

    The total informal care time received during a typical week

  4. Quantify the indirect costs associated with non-work caregiving time for companions

    Time frame: 12 months

    The indirect costs associated with the annual opportunity costs of companion

Secondary outcomes

  1. Identify the reasons for HDGEC and companion's unemployment or underemployment

    Time frame: 12 months

  2. The proportion of Dual Role Companions, differentiated by HD stage of the companion

    Time frame: 12 months

  3. To understand traditional disease staging system based on total functional capacity (TFC)

    Time frame: 12 months

    For HDGECs and Companions: Understand how the traditional disease staging system, based on the TFC score, relates to a staging system based on resource utilization questionnaire and comorbid conditions developed in Divino et al. (2013)

Sponsors and collaborators

Lead sponsor

CHDI Foundation, Inc.

Other

Collaborators

  • IQVIA Company

Registry information

Official study title

Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Aug 14, 2018
Registry last updated
Sep 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.